And of course all patients need to have insurance with low OOP costs. That can be called universal insurance, but that doesn’t mean that it must be a single government plan (ie single payer, Medicare for All). Insurance plans can, should, and do compete on quality.
-
Prikaži ovu nit
-
But instead of competing to charge the lowest premiums by trying to figure out how to deliver proper insurance (ie. pay for treatments you need when you fall ill) more efficiently, insurers keep costs down by jamming plans full of loopholes. Like less honest Swiss cheese.
1 reply 0 proslijeđenih tweetova 3 korisnika označavaju da im se sviđaPrikaži ovu nit -
They used to discriminate on the basis of pre-existing conditions (remember?), refusing to pay for a woman’s treatment for recurrent breast cancer because she had beaten it once before when she was on a different plan. That kept premiums down but left patients hanging.
1 reply 0 proslijeđenih tweetova 2 korisnika označavaju da im se sviđaPrikaži ovu nit -
Congress outlawed that practice. So plans switched to increasing deductibles and copays, more broadly discriminating against the sick when that’s who it’s for. There are even loopholes so clever that an insurance company can make more off of you when you get sick. Here’s how:
1 reply 0 proslijeđenih tweetova 2 korisnika označavaju da im se sviđaPrikaži ovu nit -
Let’s say you need insulin. Your plan has negotiated a big rebate from the drug company for that insulin. You have to pay full price out of your deductible but your insurance keeps the rebate. Congress knows about this tactic and is working to close it.
1 reply 0 proslijeđenih tweetova 3 korisnika označavaju da im se sviđaPrikaži ovu nit -
The point is that $271B is affordable for America and can be affordable for patients but only if patients have proper insurance. The trouble is that right now only about $210B is sourced from taxes and premiums and $61B is charged to patients as OOP costs. (Source: IQVIA)
1 reply 0 proslijeđenih tweetova 4 korisnika označavaju da im se sviđaPrikaži ovu nit -
In the context of nearly $3T collected in total in taxes and insurance premiums for healthcare (the vast majority going to doctors and hospitals), leaving out the $61B (2%) that makes drugs unaffordable to some seems a bit arbitrary. You can’t say that 2% is unaffordable.
1 reply 2 proslijeđena tweeta 7 korisnika označava da im se sviđaPrikaži ovu nit -
It would take ~2% increase in premiums to make branded drugs affordable to patients. Considering our nation’s $17.6B in personal income, it would take a 0.3% rise in taxes to pay for all OOP costs. Not impossible - just a choice.
1 reply 0 proslijeđenih tweetova 2 korisnika označavaju da im se sviđaPrikaži ovu nit -
And only a fraction of OOP costs are unaffordable; many people are reasonably healthy, have jobs, and can cover their OOP costs. If we shifted even $20B of OOP costs to premiums or taxes to ease the burden on the hardest hit patients, we would solve affordability. Tiny shift.
1 reply 0 proslijeđenih tweetova 2 korisnika označavaju da im se sviđaPrikaži ovu nit -
Back to question 2. Though America can afford and should afford (to signal their importance to drug developers) to spend $271B on branded drugs, using proper insurance to shield patients from that cost, can’t we spend less? We overlook that we soon will.
1 reply 0 proslijeđenih tweetova 1 korisnik označava da mu se sviđaPrikaži ovu nit
Unlike spending on hospital, which is an eternal rent, branded drugs will go generic (and I propose regulations for the few that don’t yet), and remain useful forever, offering us a bargain. Our parents paid off the drugs that are our generics today. Shall we invest for our kids?
-
-
Odgovor korisniku/ci @PeterKolchinsky
"Quality" of the insurance plan and "investing for your kids" do not have an attached monetary value. Therefore, they would *never* be part of the strategy of *any* insurance company. And this is exactly why, just like education, healthcare should not follow the markets, 1/2
1 reply 0 proslijeđenih tweetova 0 korisnika označava da im se sviđa - Još 4 druga odgovora
Novi razgovor -
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.